Michael J. Rybak, PharmD, PhD, MPH

Professor
Eugene Applebaum College of Pharmacy and Health Sciences

Disclosure(s): Abbvie, Melinta, Sionogi, Merck, T2Biosystems: Advisor/Consultant, Grant/Research Support, Speaker

Poster(s):

• (P-289) Short-Duration vs. Long-Duration of Therapy for Hospital-Acquired or Ventilator-Associated Pneumonia due to Multi-Drug Resistant Pseudomonas aeruginosa
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1499) Patient Characteristics and Clinical Outcomes Associated with Meropenem/Vaborbactam Treatment in Carbapenem-Resistant Enterobacterales Pneumonia
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1500) Evaluation of Imipenem-cilastatin-relebactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1801) Optimizing Antimicrobial Therapy in Gram-Negative Bloodstream Infections: Insights from a Pharmacist-Driven Intervention Leveraging Molecular Rapid Diagnostic Testing
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2082) Shifting Susceptibility: MIC Assessment in RPMI versus MHB for Daptomycin Non-Susceptible MRSA Isolates
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT